Page last updated: 2024-12-11

lu 28-179

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

Lu 28-179: sigma(2) ligand and lysosomotropic agent; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID9829526
CHEMBL ID61479
SCHEMBL ID2090079
MeSH IDM0284482

Synonyms (31)

Synonym
bdbm50035105
1''-{4-[1-(4-fluorophenyl)-1h-3-indolyl]butyl}spiro[1,3-dihydroisobenzofuran-1,4''-(hexahydropyridine)](lu 28-179)
lu 28-179
1''-{4-[1-(4-fluorophenyl)-1h-3-indolyl]butyl}spiro[1,3-dihydroisobenzofuran-1,4''-(hexahydropyridine)]
siramesine
CHEMBL61479 ,
lu-28-179
3ix8cwr24v ,
1'-(4-(1-(p-fluorophenyl)indol-3-yl)butyl)spiro(phthalan-1,4'-piperidine)
siramesine [inn]
147817-50-3
unii-3ix8cwr24v
HY-14221
CS-1920
XWAONOGAGZNUSF-UHFFFAOYSA-N
1'-[4-[1-(4-fluorophenyl)-1h-indole-3-yl]-1-butyl]-spiro[isobenzofuran-1(3h),4'-piperidine]
siramesine(lu 28-179)
SCHEMBL2090079
1'-(4-(1-(4-fluorophenyl)-1h-indol-3-yl)butyl)-3h-spiro[isobenzofuran-1,4'-piperidine]
DTXSID90163810
spiro[isobenzofuran-1(3h),4'-piperidine], 1'-[4-[1-(4-fluorophenyl)-1h-indol-3-yl]butyl]-
EX-A355
AKOS027251054
mfcd00912182
1'-[4-[1-(4-fluorophenyl)indol-3-yl]butyl]spiro[1h-2-benzofuran-3,4'-piperidine]
NCGC00370727-06
BCP08745
lu-28-179; lu 28-179; lu28-179; lu-28179; lu 28179; lu28179
DB06555
Q7529961
A857438

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
" Despite promising in vitro properties the prodrugs were unable to improve the oral bioavailability of Lu 28-179 as compared to that obtained after administration of a reference formulation of the parent drug in the dog."( Bioreversible quaternary N-acyloxymethyl derivatives of the poorly soluble tertiary amine Lu 28-179--synthesis, pharmaceutical chemical characterization and bioavailability studies in dogs.
Buur, A; Larsen, C; Nielsen, AB, 2005
)
0.33
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

ExcerptRelevanceReference
" Lu 28-179 and BD 1008 potentiated dose-dependently the NMDA response and generated bell-shaped dose-response curves."( Modulation of the neuronal response to N-methyl-D-aspartate by selective sigma2 ligands.
Couture, S; Debonnel, G, 1998
)
0.3
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (20)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
cytochrome P450 family 3 subfamily A polypeptide 4Homo sapiens (human)Potency1.69330.01237.983543.2770AID1645841
GVesicular stomatitis virusPotency2.39190.01238.964839.8107AID1645842
cytochrome P450 2D6Homo sapiens (human)Potency0.60080.00108.379861.1304AID1645840
Interferon betaHomo sapiens (human)Potency2.39190.00339.158239.8107AID1645842
HLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)Potency2.39190.01238.964839.8107AID1645842
Inositol hexakisphosphate kinase 1Homo sapiens (human)Potency2.39190.01238.964839.8107AID1645842
cytochrome P450 2C9, partialHomo sapiens (human)Potency2.39190.01238.964839.8107AID1645842
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Cytochrome P450 3A4Homo sapiens (human)IC50 (µMol)2.00000.00011.753610.0000AID5491
5-hydroxytryptamine receptor 2ARattus norvegicus (Norway rat)IC50 (µMol)2.00000.00040.908610.0000AID5491
Alpha-1B adrenergic receptorRattus norvegicus (Norway rat)IC50 (µMol)0.33000.00021.874210.0000AID37009
5-hydroxytryptamine receptor 1ARattus norvegicus (Norway rat)IC50 (µMol)21.00000.00031.38338.4000AID4136
Alpha-1D adrenergic receptorRattus norvegicus (Norway rat)IC50 (µMol)0.33000.00021.270410.0000AID37009
Alpha-1A adrenergic receptorRattus norvegicus (Norway rat)IC50 (µMol)0.33000.00001.819410.0000AID37009
D(2) dopamine receptorRattus norvegicus (Norway rat)IC50 (µMol)0.80000.00010.54948.4000AID64613
Mu-type opioid receptorCavia porcellus (domestic guinea pig)Ki0.01700.00000.27869.0000AID1363621
Sigma intracellular receptor 2Homo sapiens (human)Ki0.00010.00010.83604.6005AID1353759
Sigma intracellular receptor 2Rattus norvegicus (Norway rat)Ki0.01700.00241.10509.3000AID1353758
Sigma non-opioid intracellular receptor 1Cavia porcellus (domestic guinea pig)Ki0.01700.00000.338510.0000AID1143314; AID1363621
Sigma non-opioid intracellular receptor 1Homo sapiens (human)IC50 (µMol)0.01700.00030.70285.3660AID204763
Sigma non-opioid intracellular receptor 1Homo sapiens (human)Ki0.01700.00000.490110.0000AID1127667; AID1143314; AID1353758; AID619421
Sigma non-opioid intracellular receptor 1Rattus norvegicus (Norway rat)IC50 (µMol)0.01700.00030.55704.2000AID204762; AID204763
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (75)

Processvia Protein(s)Taxonomy
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell activation involved in immune responseInterferon betaHomo sapiens (human)
cell surface receptor signaling pathwayInterferon betaHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to virusInterferon betaHomo sapiens (human)
positive regulation of autophagyInterferon betaHomo sapiens (human)
cytokine-mediated signaling pathwayInterferon betaHomo sapiens (human)
natural killer cell activationInterferon betaHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT proteinInterferon betaHomo sapiens (human)
cellular response to interferon-betaInterferon betaHomo sapiens (human)
B cell proliferationInterferon betaHomo sapiens (human)
negative regulation of viral genome replicationInterferon betaHomo sapiens (human)
innate immune responseInterferon betaHomo sapiens (human)
positive regulation of innate immune responseInterferon betaHomo sapiens (human)
regulation of MHC class I biosynthetic processInterferon betaHomo sapiens (human)
negative regulation of T cell differentiationInterferon betaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIInterferon betaHomo sapiens (human)
defense response to virusInterferon betaHomo sapiens (human)
type I interferon-mediated signaling pathwayInterferon betaHomo sapiens (human)
neuron cellular homeostasisInterferon betaHomo sapiens (human)
cellular response to exogenous dsRNAInterferon betaHomo sapiens (human)
cellular response to virusInterferon betaHomo sapiens (human)
negative regulation of Lewy body formationInterferon betaHomo sapiens (human)
negative regulation of T-helper 2 cell cytokine productionInterferon betaHomo sapiens (human)
positive regulation of apoptotic signaling pathwayInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell differentiationInterferon betaHomo sapiens (human)
natural killer cell activation involved in immune responseInterferon betaHomo sapiens (human)
adaptive immune responseInterferon betaHomo sapiens (human)
T cell activation involved in immune responseInterferon betaHomo sapiens (human)
humoral immune responseInterferon betaHomo sapiens (human)
positive regulation of T cell mediated cytotoxicityHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
adaptive immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway, TAP-independentHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of T cell anergyHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
defense responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
detection of bacteriumHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of interleukin-12 productionHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of interleukin-6 productionHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protection from natural killer cell mediated cytotoxicityHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
innate immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of dendritic cell differentiationHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class IbHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
lipid hydroxylationCytochrome P450 3A4Homo sapiens (human)
lipid metabolic processCytochrome P450 3A4Homo sapiens (human)
steroid catabolic processCytochrome P450 3A4Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 3A4Homo sapiens (human)
steroid metabolic processCytochrome P450 3A4Homo sapiens (human)
cholesterol metabolic processCytochrome P450 3A4Homo sapiens (human)
androgen metabolic processCytochrome P450 3A4Homo sapiens (human)
estrogen metabolic processCytochrome P450 3A4Homo sapiens (human)
alkaloid catabolic processCytochrome P450 3A4Homo sapiens (human)
monoterpenoid metabolic processCytochrome P450 3A4Homo sapiens (human)
calcitriol biosynthetic process from calciolCytochrome P450 3A4Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 3A4Homo sapiens (human)
vitamin D metabolic processCytochrome P450 3A4Homo sapiens (human)
vitamin D catabolic processCytochrome P450 3A4Homo sapiens (human)
retinol metabolic processCytochrome P450 3A4Homo sapiens (human)
retinoic acid metabolic processCytochrome P450 3A4Homo sapiens (human)
long-chain fatty acid biosynthetic processCytochrome P450 3A4Homo sapiens (human)
aflatoxin metabolic processCytochrome P450 3A4Homo sapiens (human)
oxidative demethylationCytochrome P450 3A4Homo sapiens (human)
regulation of cell growthSigma intracellular receptor 2Homo sapiens (human)
regulation of intracellular lipid transportSigma intracellular receptor 2Homo sapiens (human)
regulation of intracellular cholesterol transportSigma intracellular receptor 2Homo sapiens (human)
cholesterol homeostasisSigma intracellular receptor 2Homo sapiens (human)
positive regulation of wound healingSigma intracellular receptor 2Homo sapiens (human)
positive regulation of lipoprotein transportSigma intracellular receptor 2Homo sapiens (human)
inositol phosphate metabolic processInositol hexakisphosphate kinase 1Homo sapiens (human)
phosphatidylinositol phosphate biosynthetic processInositol hexakisphosphate kinase 1Homo sapiens (human)
negative regulation of cold-induced thermogenesisInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol phosphate biosynthetic processInositol hexakisphosphate kinase 1Homo sapiens (human)
lipid transportSigma non-opioid intracellular receptor 1Homo sapiens (human)
nervous system developmentSigma non-opioid intracellular receptor 1Homo sapiens (human)
G protein-coupled opioid receptor signaling pathwaySigma non-opioid intracellular receptor 1Homo sapiens (human)
regulation of neuron apoptotic processSigma non-opioid intracellular receptor 1Homo sapiens (human)
protein homotrimerizationSigma non-opioid intracellular receptor 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (43)

Processvia Protein(s)Taxonomy
cytokine activityInterferon betaHomo sapiens (human)
cytokine receptor bindingInterferon betaHomo sapiens (human)
type I interferon receptor bindingInterferon betaHomo sapiens (human)
protein bindingInterferon betaHomo sapiens (human)
chloramphenicol O-acetyltransferase activityInterferon betaHomo sapiens (human)
TAP bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
signaling receptor bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
peptide antigen bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
TAP bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein-folding chaperone bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
monooxygenase activityCytochrome P450 3A4Homo sapiens (human)
steroid bindingCytochrome P450 3A4Homo sapiens (human)
iron ion bindingCytochrome P450 3A4Homo sapiens (human)
protein bindingCytochrome P450 3A4Homo sapiens (human)
steroid hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
retinoic acid 4-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
oxidoreductase activityCytochrome P450 3A4Homo sapiens (human)
oxygen bindingCytochrome P450 3A4Homo sapiens (human)
enzyme bindingCytochrome P450 3A4Homo sapiens (human)
heme bindingCytochrome P450 3A4Homo sapiens (human)
vitamin D3 25-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
caffeine oxidase activityCytochrome P450 3A4Homo sapiens (human)
quinine 3-monooxygenase activityCytochrome P450 3A4Homo sapiens (human)
testosterone 6-beta-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
1-alpha,25-dihydroxyvitamin D3 23-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
anandamide 8,9 epoxidase activityCytochrome P450 3A4Homo sapiens (human)
anandamide 11,12 epoxidase activityCytochrome P450 3A4Homo sapiens (human)
anandamide 14,15 epoxidase activityCytochrome P450 3A4Homo sapiens (human)
aromatase activityCytochrome P450 3A4Homo sapiens (human)
vitamin D 24-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
estrogen 16-alpha-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
estrogen 2-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
1,8-cineole 2-exo-monooxygenase activityCytochrome P450 3A4Homo sapiens (human)
protein bindingSigma intracellular receptor 2Homo sapiens (human)
oxysterol bindingSigma intracellular receptor 2Homo sapiens (human)
cholesterol bindingSigma intracellular receptor 2Homo sapiens (human)
inositol-1,3,4,5,6-pentakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol heptakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 5-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
protein bindingInositol hexakisphosphate kinase 1Homo sapiens (human)
ATP bindingInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 1-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 3-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol 5-diphosphate pentakisphosphate 5-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol diphosphate tetrakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
G protein-coupled opioid receptor activitySigma non-opioid intracellular receptor 1Homo sapiens (human)
protein bindingSigma non-opioid intracellular receptor 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (37)

Processvia Protein(s)Taxonomy
extracellular spaceInterferon betaHomo sapiens (human)
extracellular regionInterferon betaHomo sapiens (human)
Golgi membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
endoplasmic reticulumHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
Golgi apparatusHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
plasma membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
cell surfaceHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
ER to Golgi transport vesicle membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
secretory granule membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
phagocytic vesicle membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
early endosome membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
recycling endosome membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular exosomeHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
lumenal side of endoplasmic reticulum membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
MHC class I protein complexHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular spaceHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
external side of plasma membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
cytoplasmCytochrome P450 3A4Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 3A4Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 3A4Homo sapiens (human)
endoplasmic reticulumSigma intracellular receptor 2Homo sapiens (human)
lysosomeSigma intracellular receptor 2Homo sapiens (human)
endoplasmic reticulumSigma intracellular receptor 2Homo sapiens (human)
rough endoplasmic reticulumSigma intracellular receptor 2Homo sapiens (human)
plasma membraneSigma intracellular receptor 2Homo sapiens (human)
rough endoplasmic reticulum membraneSigma intracellular receptor 2Homo sapiens (human)
nuclear membraneSigma intracellular receptor 2Homo sapiens (human)
fibrillar centerInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleoplasmInositol hexakisphosphate kinase 1Homo sapiens (human)
cytosolInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleusInositol hexakisphosphate kinase 1Homo sapiens (human)
cytoplasmInositol hexakisphosphate kinase 1Homo sapiens (human)
nuclear envelopeSigma non-opioid intracellular receptor 1Homo sapiens (human)
nuclear inner membraneSigma non-opioid intracellular receptor 1Homo sapiens (human)
nuclear outer membraneSigma non-opioid intracellular receptor 1Homo sapiens (human)
endoplasmic reticulumSigma non-opioid intracellular receptor 1Homo sapiens (human)
endoplasmic reticulum membraneSigma non-opioid intracellular receptor 1Homo sapiens (human)
lipid dropletSigma non-opioid intracellular receptor 1Homo sapiens (human)
cytosolSigma non-opioid intracellular receptor 1Homo sapiens (human)
postsynaptic densitySigma non-opioid intracellular receptor 1Homo sapiens (human)
membraneSigma non-opioid intracellular receptor 1Homo sapiens (human)
growth coneSigma non-opioid intracellular receptor 1Homo sapiens (human)
cytoplasmic vesicleSigma non-opioid intracellular receptor 1Homo sapiens (human)
anchoring junctionSigma non-opioid intracellular receptor 1Homo sapiens (human)
postsynaptic density membraneSigma non-opioid intracellular receptor 1Homo sapiens (human)
endoplasmic reticulumSigma non-opioid intracellular receptor 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (47)

Assay IDTitleYearJournalArticle
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347159Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347160Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1143328Antagonist activity at sigma-2 receptor in mouse EMT6 cells assessed as inhibition of cell proliferation after 48 hrs by MTS assay2014Journal of medicinal chemistry, May-22, Volume: 57, Issue:10
Synthesis and structure-activity relationship studies of conformationally flexible tetrahydroisoquinolinyl triazole carboxamide and triazole substituted benzamide analogues as σ2 receptor ligands.
AID1337386Displacement of [3H](+)pentazocine from sigma 1 receptor in rat brain homogenates without cerebellum2016European journal of medicinal chemistry, Nov-29, Volume: 124Synthesis and biological evaluation of new aryl-alkyl(alkenyl)-4-benzylpiperidines, novel Sigma Receptor (SR) modulators, as potential anticancer-agents.
AID1861729Cytotoxicity against ER/PR-negative HER2-positive human SK-BR-3 cells harbouring wild type p53 assessed as inhibition of cell growth incubated for 48 hrs by resazurin dye based assay2022Bioorganic & medicinal chemistry letters, 09-15, Volume: 72Design, synthesis and biological evaluation of novel aminopropylcarboxamide derivatives as sigma ligands.
AID1363621Displacement of [3H]-(+)-pentazocine from sigma1 receptor in guinea pig brain cortex membranes incubated for 120 mins by scintillation counting method2018Journal of medicinal chemistry, 11-08, Volume: 61, Issue:21
Synthesis, Receptor Affinity, and Antiallodynic Activity of Spirocyclic σ Receptor Ligands with Exocyclic Amino Moiety.
AID1337387Displacement of [3H]DTG from sigma 2 receptor in rat brain homogenates without cerebellum2016European journal of medicinal chemistry, Nov-29, Volume: 124Synthesis and biological evaluation of new aryl-alkyl(alkenyl)-4-benzylpiperidines, novel Sigma Receptor (SR) modulators, as potential anticancer-agents.
AID1861730Cytotoxicity against ER/PR-positive HER2-negative human MCF7 cells harbouring p53 R175H mutant assessed as inhibition of cell growth incubated for 48 hrs by resazurin dye based assay2022Bioorganic & medicinal chemistry letters, 09-15, Volume: 72Design, synthesis and biological evaluation of novel aminopropylcarboxamide derivatives as sigma ligands.
AID204763Binding affinity towards sigma receptor binding site 1 using [3H](+)-pentazocine1995Journal of medicinal chemistry, May-26, Volume: 38, Issue:11
Sigma ligands with subnanomolar affinity and preference for the sigma 2 binding site. 1. 3-(omega-aminoalkyl)-1H-indoles.
AID4136Binding affinity towards 5-hydroxytryptamine 1A receptor binding site using [3H]8-OH-DPAT. 1995Journal of medicinal chemistry, May-26, Volume: 38, Issue:11
Sigma ligands with subnanomolar affinity and preference for the sigma 2 binding site. 1. 3-(omega-aminoalkyl)-1H-indoles.
AID204764Ratio of the binding affinities against Sigma receptor type 1 and Sigma receptor type 21995Journal of medicinal chemistry, May-26, Volume: 38, Issue:11
Sigma ligands with subnanomolar affinity and preference for the sigma 2 binding site. 2. Spiro-joined benzofuran, isobenzofuran, and benzopyran piperidines.
AID1143314Binding affinity to sigma-1 receptor (unknown origin)2014Journal of medicinal chemistry, May-22, Volume: 57, Issue:10
Synthesis and structure-activity relationship studies of conformationally flexible tetrahydroisoquinolinyl triazole carboxamide and triazole substituted benzamide analogues as σ2 receptor ligands.
AID1127667Binding affinity to sigma-1 opioid receptor (unknown origin)2013Journal of medicinal chemistry, Sep-26, Volume: 56, Issue:18
The σ2 receptor: a novel protein for the imaging and treatment of cancer.
AID1420180Cytotoxicity against human SH-SY5Y cells at 50 uM after 48 hrs by MTT assay2018Bioorganic & medicinal chemistry letters, 10-15, Volume: 28, Issue:19
New piperidine-based derivatives as sigma receptor ligands. Synthesis and pharmacological evaluation.
AID1353759Binding affinity to sigma-2 receptor (unknown origin)2018European journal of medicinal chemistry, Mar-10, Volume: 147Synthesis and pharmacological evaluation of 6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline derivatives as sigma-2 receptor ligands.
AID5491Binding affinity towards 5-hydroxytryptamine 2A receptor binding site using [3H]ketanserin. 1995Journal of medicinal chemistry, May-26, Volume: 38, Issue:11
Sigma ligands with subnanomolar affinity and preference for the sigma 2 binding site. 1. 3-(omega-aminoalkyl)-1H-indoles.
AID1143321Antagonist activity at sigma-2 receptor in mouse EMT6 cells assessed as inhibition of cell proliferation after 24 hrs by MTS assay2014Journal of medicinal chemistry, May-22, Volume: 57, Issue:10
Synthesis and structure-activity relationship studies of conformationally flexible tetrahydroisoquinolinyl triazole carboxamide and triazole substituted benzamide analogues as σ2 receptor ligands.
AID1143316Selectivity ratio of Ki for sigma-1 receptor (unknown origin) to Ki for sigma-2 receptor (unknown origin)2014Journal of medicinal chemistry, May-22, Volume: 57, Issue:10
Synthesis and structure-activity relationship studies of conformationally flexible tetrahydroisoquinolinyl triazole carboxamide and triazole substituted benzamide analogues as σ2 receptor ligands.
AID204762Compound was evaluated for the binding affinity towards Sigma receptor type 1 using radioligand ([3H]-(+)- Pentazocine) binding assay.1995Journal of medicinal chemistry, May-26, Volume: 38, Issue:11
Sigma ligands with subnanomolar affinity and preference for the sigma 2 binding site. 2. Spiro-joined benzofuran, isobenzofuran, and benzopyran piperidines.
AID1363622Displacement of [3H]-di-o-tolylguanidine from sigma2 receptor in rat liver membranes incubated for 120 mins by scintillation counting method2018Journal of medicinal chemistry, 11-08, Volume: 61, Issue:21
Synthesis, Receptor Affinity, and Antiallodynic Activity of Spirocyclic σ Receptor Ligands with Exocyclic Amino Moiety.
AID230925Binding affinities for sigma-1 and sigma 2 receptors, ratio of IC501995Journal of medicinal chemistry, May-26, Volume: 38, Issue:11
Sigma ligands with subnanomolar affinity and preference for the sigma 2 binding site. 1. 3-(omega-aminoalkyl)-1H-indoles.
AID204770Binding affinity towards Sigma receptor site 2 in rat brain using [3H]DTG as radioligand1995Journal of medicinal chemistry, May-26, Volume: 38, Issue:11
Sigma ligands with subnanomolar affinity and preference for the sigma 2 binding site. 2. Spiro-joined benzofuran, isobenzofuran, and benzopyran piperidines.
AID1409614Overall antiviral activity against SARS-CoV-2 (isolate France/IDF0372/2020) in the Vero E6 cell line at 48 h based on three assays 1) detection of viral RNA by qRT-PCR (targeting the N-gene), 2) plaque assay using lysate 3 days after addition of compound 2020Nature, 07, Volume: 583, Issue:7816
A SARS-CoV-2 protein interaction map reveals targets for drug repurposing.
AID619422Binding affinity to sigma 2 receptor2011European journal of medicinal chemistry, Oct, Volume: 46, Issue:10
Synthesis and pharmacological evaluation of indole-based sigma receptor ligands.
AID64613Binding affinity towards Dopamine receptor D2 binding site using [3H]spiroperidol.1995Journal of medicinal chemistry, May-26, Volume: 38, Issue:11
Sigma ligands with subnanomolar affinity and preference for the sigma 2 binding site. 1. 3-(omega-aminoalkyl)-1H-indoles.
AID1337354Cytotoxicity against human Paca3 cells assessed as decrease in cell viability under starvation condition after 24 hrs by MTS assay2016European journal of medicinal chemistry, Nov-29, Volume: 124Synthesis and biological evaluation of new aryl-alkyl(alkenyl)-4-benzylpiperidines, novel Sigma Receptor (SR) modulators, as potential anticancer-agents.
AID204772Binding affinity towards sigma receptor binding site 2 using [3H]DTG of whole rat brain homogenates except cerebellum1995Journal of medicinal chemistry, May-26, Volume: 38, Issue:11
Sigma ligands with subnanomolar affinity and preference for the sigma 2 binding site. 1. 3-(omega-aminoalkyl)-1H-indoles.
AID386938Selectivity ratio of IC50 for rat sigma 1 receptor to IC50 for rat sigma 2 receptor2008European journal of medicinal chemistry, Oct, Volume: 43, Issue:10
Substituted benzylaminoalkylindoles with preference for the sigma2 binding site.
AID1861731Cytotoxicity against ER/PR-negative HER2-positive human SK-BR-3 cells harbouring wild type p53 assessed as reduction in cell viability at 100 to 200 uM incubated for 48 hrs by resazurin dye based assay relative to control2022Bioorganic & medicinal chemistry letters, 09-15, Volume: 72Design, synthesis and biological evaluation of novel aminopropylcarboxamide derivatives as sigma ligands.
AID619421Binding affinity to sigma 1 receptor2011European journal of medicinal chemistry, Oct, Volume: 46, Issue:10
Synthesis and pharmacological evaluation of indole-based sigma receptor ligands.
AID1127668Binding affinity to sigma-2 opioid receptor (unknown origin)2013Journal of medicinal chemistry, Sep-26, Volume: 56, Issue:18
The σ2 receptor: a novel protein for the imaging and treatment of cancer.
AID1363643Displacement of [3H]-DTG from sigma2 receptor in rat liver membranes2018Journal of medicinal chemistry, 11-08, Volume: 61, Issue:21
Synthesis, Receptor Affinity, and Antiallodynic Activity of Spirocyclic σ Receptor Ligands with Exocyclic Amino Moiety.
AID1143315Binding affinity to sigma-2 receptor (unknown origin)2014Journal of medicinal chemistry, May-22, Volume: 57, Issue:10
Synthesis and structure-activity relationship studies of conformationally flexible tetrahydroisoquinolinyl triazole carboxamide and triazole substituted benzamide analogues as σ2 receptor ligands.
AID37009Binding affinity for Alpha-1 adrenergic receptor with [3H]prazosin1995Journal of medicinal chemistry, May-26, Volume: 38, Issue:11
Sigma ligands with subnanomolar affinity and preference for the sigma 2 binding site. 1. 3-(omega-aminoalkyl)-1H-indoles.
AID1861732Cytotoxicity against ER/PR-positive HER2-negative human MCF7 cells harbouring p53 R175H mutant assessed as reduction in cell viability at 100 uM incubated for 48 hrs by resazurin dye based assay relative to control2022Bioorganic & medicinal chemistry letters, 09-15, Volume: 72Design, synthesis and biological evaluation of novel aminopropylcarboxamide derivatives as sigma ligands.
AID1337353Cytotoxicity against human Paca3 cells assessed as decrease in cell viability using complete medium after 24 hrs by MTS assay2016European journal of medicinal chemistry, Nov-29, Volume: 124Synthesis and biological evaluation of new aryl-alkyl(alkenyl)-4-benzylpiperidines, novel Sigma Receptor (SR) modulators, as potential anticancer-agents.
AID1353758Binding affinity to sigma-1 receptor (unknown origin)2018European journal of medicinal chemistry, Mar-10, Volume: 147Synthesis and pharmacological evaluation of 6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline derivatives as sigma-2 receptor ligands.
AID386942Displacement of [3H] (+)-pentazocine from sigma 1 receptor in rat liver homogenate2008European journal of medicinal chemistry, Oct, Volume: 43, Issue:10
Substituted benzylaminoalkylindoles with preference for the sigma2 binding site.
AID386940Displacement of [3H]DTH from sigma 2 receptor in rat liver homogenate in presence of (+)-pentazocine2008European journal of medicinal chemistry, Oct, Volume: 43, Issue:10
Substituted benzylaminoalkylindoles with preference for the sigma2 binding site.
AID1363642Displacement of [3H](+)-pentazocine from sigma1 receptor in quinea pig brain membranes2018Journal of medicinal chemistry, 11-08, Volume: 61, Issue:21
Synthesis, Receptor Affinity, and Antiallodynic Activity of Spirocyclic σ Receptor Ligands with Exocyclic Amino Moiety.
AID1420188Cytotoxicity against human PANC1 cells at 50 uM after 48 hrs by MTT assay2018Bioorganic & medicinal chemistry letters, 10-15, Volume: 28, Issue:19
New piperidine-based derivatives as sigma receptor ligands. Synthesis and pharmacological evaluation.
AID1143317Lipophilicity, log P of the compound2014Journal of medicinal chemistry, May-22, Volume: 57, Issue:10
Synthesis and structure-activity relationship studies of conformationally flexible tetrahydroisoquinolinyl triazole carboxamide and triazole substituted benzamide analogues as σ2 receptor ligands.
AID1127656Selectivity ratio of IC50 for sigma-1 opioid receptor (unknown origin) to IC50 for sigma-2 opioid receptor (unknown origin)2013Journal of medicinal chemistry, Sep-26, Volume: 56, Issue:18
The σ2 receptor: a novel protein for the imaging and treatment of cancer.
AID1727496Agonist activity at sigma 2 receptor in human MCF7 cells assessed as stimulation of intracellular calcium release at 10 uM incubated for 3 hrs by Fluo-3 AM dye based confocal laser scanning microscopy
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (52)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's4 (7.69)18.2507
2000's17 (32.69)29.6817
2010's22 (42.31)24.3611
2020's9 (17.31)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews3 (5.77%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other49 (94.23%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]